Jens Quant
- Cell Biology top 2%
- Microtubule and mitosis dynamics 5
- Oncology top 5%
- Cancer-related Molecular Pathways 10
- Cancer Treatment and Pharmacology 2
- Cancer Immunotherapy and Biomarkers 2
- Molecular Biology top 10%
- Cancer Research top 10%
- Cancer, Hypoxia, and Metabolism 5
-
- Growth Hormone and Insulin-like Growth Factors 3
-
- Cancer Research and Treatments 2
-
- Immunotherapy and Immune Responses 2
- Co-authors
- Pilar Garin‐ChesaWolfgang J. RettigMartin KrššákGünther R. AdolfAnke BaumMatthias HoffmannMartin SteegmaierMatthias Grauert
- Journals
- Cancer Research (6 papers)Molecular Cancer Therapeutics (2 papers)Cancer Chemotherapy and Pharmacology (2 papers)
- Partner nations
- AustriaGermanyUnited Kingdom
In The Last Decade
Jens Quant
14 papers receiving 2.0k citations
Hit Papers
Peers
Comparison fields: 5 of 85
- Cell Biology 684
- Oncology 732
- Pulmonary and Respiratory Medicine 562
- Molecular Biology 1.1k
- Cancer Research 186
Countries citing papers authored by Jens Quant
This map shows the geographic impact of Jens Quant's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jens Quant with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jens Quant more than expected).
Fields of papers citing papers by Jens Quant
This network shows the impact of papers produced by Jens Quant. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jens Quant. The network helps show where Jens Quant may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Jens Quant, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2018 | 46 | |
| 2 | 2018 | 4 | |
| 3 | 2018 | 12 | |
| 4 | 2018 | 9 | |
| 5 | 2017 | 6 | |
| 6 | 2017 | 0 | |
| 7 | 2016 | 28 | |
| 8 | 2016 | 5 | |
| 9 | 2015 | 16 | |
| 10 | 2010 | 12 | |
| 11 | 2010 | 1 | |
| 12 | 2009 | 322 | |
| 13 | BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacybreakdown → | 2008 | 861 |
| 14 | 2008 | 5 | |
| 15 | BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivobreakdown → | 2007 | 691 |
About Jens Quant
Jens Quant is a scholar working on Oncology, Cancer Research, Cell Biology, Biotechnology and Endocrinology, Diabetes and Metabolism, having authored 15 papers that have together received 2.0k indexed citations. Recurring topics across this work include Cancer-related Molecular Pathways (10 papers), Cancer, Hypoxia, and Metabolism (5 papers), Microtubule and mitosis dynamics (5 papers), Growth Hormone and Insulin-like Growth Factors (3 papers), Cancer Research and Treatments (2 papers), Immunotherapy and Immune Responses (2 papers), Cancer Treatment and Pharmacology (2 papers) and Cancer Immunotherapy and Biomarkers (2 papers). The work is most often cited by research in Cell Biology (684 citations), Oncology (732 citations), Pulmonary and Respiratory Medicine (562 citations), Molecular Biology (1.1k citations) and Cancer Research (186 citations). Jens Quant has collaborated with scholars based in Austria, Germany and United Kingdom. Frequent co-authors include Pilar Garin‐Chesa, Wolfgang J. Rettig, Martin Krššák, Günther R. Adolf, Anke Baum, Matthias Hoffmann, Martin Steegmaier, Matthias Grauert, Andreas Zoephel and Gerd Bader. Their work appears in journals such as Cancer Research, Molecular Cancer Therapeutics, Cancer Chemotherapy and Pharmacology, Journal of Clinical Oncology and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.